Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Prevention and Control of Anemia Amongst Children and Adolescents: Theory and Practice in India.

Kapil U, Kapil R, Gupta A.

Indian J Pediatr. 2019 Jun;86(6):523-531. doi: 10.1007/s12098-019-02932-5. Epub 2019 May 11.

PMID:
31079321
2.

Reduction in prevalence of anaemia in pregnant women.

Gupta A, Kapil R, Kapil U.

Indian J Med Res. 2018 Sep;148(3):345-346. doi: 10.4103/ijmr.IJMR_1429_18. No abstract available.

3.

Anemia, Iron Deficiency and Iodine Deficiency among Nepalese School Children: Correspondence.

Kapil R, Gupta A.

Indian J Pediatr. 2018 Jun;85(6):487-488. doi: 10.1007/s12098-017-2581-0. Epub 2018 Jan 4. No abstract available.

PMID:
29302864
4.

T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions.

Ogendi BMO, Bakshi RK, Gupta K, Kapil R, Brown LT, Jordan SJ, Sabbaj S, Press CG, Lee JY, Geisler WM.

Microbes Infect. 2018 Mar;20(3):176-184. doi: 10.1016/j.micinf.2017.12.001. Epub 2017 Dec 26.

5.

Distinct peripheral vs mucosal T-cell phenotypes in chlamydia-infected women.

Ogendi BMO, Bakshi RK, Sabbaj S, Brown L, Lee JY, Kapil R, Geisler WM.

Am J Reprod Immunol. 2017 Dec;78(6). doi: 10.1111/aji.12768. Epub 2017 Sep 26.

6.

Relationship between Amphipathic β Structures in the β1 Domain of Apolipoprotein B and the Properties of the Secreted Lipoprotein Particles in McA-RH7777 Cells.

Manchekar M, Kapil R, Sun Z, Segrest JP, Dashti N.

Biochemistry. 2017 Aug 8;56(31):4084-4094. doi: 10.1021/acs.biochem.6b01174. Epub 2017 Jul 28.

PMID:
28702990
7.

The Predominant CD4+ Th1 Cytokine Elicited to Chlamydia trachomatis Infection in Women Is Tumor Necrosis Factor Alpha and Not Interferon Gamma.

Jordan SJ, Gupta K, Ogendi BMO, Bakshi RK, Kapil R, Press CG, Sabbaj S, Lee JY, Geisler WM.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00010-17. doi: 10.1128/CVI.00010-17. Print 2017 Apr.

8.

In response to Gudin et al. - Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Crudele NT, Giordano J, Kapil RP, Randhawa AS.

Pain Med. 2017 May 1;18(5):990-991. doi: 10.1093/pm/pnw278. No abstract available.

9.

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Harris SC, Cipriano A, Colucci SV, Kapil RP, Geoffroy P, Hopyan T, Levy-Cooperman N.

Pain Med. 2017 Jul 1;18(7):1278-1291. doi: 10.1093/pm/pnw208.

10.

A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.

Arendt-Nielsen L, Harris S, Whiteside GT, Hummel M, Knappenberger T, OʼKeefe S, Kapil R, Kyle D.

Pain. 2016 Sep;157(9):2057-67. doi: 10.1097/j.pain.0000000000000610.

PMID:
27168361
11.

Effect of Supplementation with Iron Fortified Biscuits on the Hemoglobin Status of Children in Rural Areas of Shimoga, Karnataka: Correspondence.

Sareen N, Gupta A, Kapil R.

Indian J Pediatr. 2016 Oct;83(10):1214. doi: 10.1007/s12098-016-2122-2. Epub 2016 May 11. No abstract available.

PMID:
27165473
12.

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Harris SC, Cipriano A, Colucci SV, Kapil RP, Geoffroy P, Hopyan T, Levy-Cooperman N.

Pain Med. 2016 May;17(5):820-31. doi: 10.1093/pm/pnv004. Epub 2015 Dec 14.

13.

Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.

Kapil RP, Cipriano A, Wen W, Yu Lynch S, He E, Colucci SV, Harris SC.

Clin Ther. 2016 Feb;38(2):302-14. doi: 10.1016/j.clinthera.2015.12.003. Epub 2015 Dec 31.

14.

Effects of Paroxetine,a CYP2D6 Inhibitor, on the Pharmacokinetic Properties of Hydrocodone After Coadministration With a Single-entity,Once-daily, Extended-release HydrocodoneTablet.

Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal S, Harris SC.

Clin Ther. 2016 Jan 1;38(1):228-9. doi: 10.1016/j.clinthera.2015.10.024. Epub 2015 Nov 23. No abstract available.

PMID:
26615894
15.

Chlamydia trachomatis infection in African American women who exclusively have sex with women.

Muzny CA, Kapil R, Austin EL, Brown L, Hook EW 3rd, Geisler WM.

Int J STD AIDS. 2016 Oct;27(11):978-83. doi: 10.1177/0956462415604092. Epub 2015 Sep 18.

PMID:
26384942
16.

Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.

Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal SA, Harris SC.

Clin Ther. 2015 Oct 1;37(10):2286-96. doi: 10.1016/j.clinthera.2015.08.007. Epub 2015 Sep 6. Erratum in: Clin Ther. 2016 Jan 1;38(1):232.

17.

Hand hygiene in reducing transient flora on the hands of healthcare workers: an educational intervention.

Kapil R, Bhavsar HK, Madan M.

Indian J Med Microbiol. 2015 Jan-Mar;33(1):125-8. doi: 10.4103/0255-0857.148409.

18.

Investigating the epidemiology of repeat Chlamydia trachomatis detection after treatment by using C. trachomatis OmpA genotyping.

Kapil R, Press CG, Hwang ML, Brown L, Geisler WM.

J Clin Microbiol. 2015 Feb;53(2):546-9. doi: 10.1128/JCM.02483-14. Epub 2014 Dec 3.

19.

Lower sexually transmissible infection prevalence among lifetime exclusive women who have sex with women compared with women who have sex with women and men.

Muzny CA, Kapil R, Austin EL, Hook EW, Geisler WM.

Sex Health. 2014 Dec;11(6):592-3. doi: 10.1071/SH14181.

PMID:
25435197
20.

Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects.

Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Harris SC, Kapil RP.

Drugs Aging. 2014 Oct;31(10):731-6. doi: 10.1007/s40266-014-0211-3.

PMID:
25246162
21.

QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride.

Bansal S, Beg S, Asthana A, Garg B, Asthana GS, Kapil R, Singh B.

Drug Deliv. 2016;23(2):437-51. doi: 10.3109/10717544.2014.916771. Epub 2014 May 28.

PMID:
24865292
22.

MP3: a software tool for the prediction of pathogenic proteins in genomic and metagenomic data.

Gupta A, Kapil R, Dhakan DB, Sharma VK.

PLoS One. 2014 Apr 15;9(4):e93907. doi: 10.1371/journal.pone.0093907. eCollection 2014.

23.

Oral health status and treatment needs among 12- and 15-year-old government and private school children in Shimla city, Himachal Pradesh, India.

Shailee F, Girish MS, Kapil RS, Nidhi P.

J Int Soc Prev Community Dent. 2013 Jan;3(1):44-50. doi: 10.4103/2231-0762.115715.

24.

Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration.

Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP.

J Clin Pharmacol. 2014 Mar;54(3):282-90. doi: 10.1002/jcph.220. Epub 2013 Nov 27.

PMID:
24203450
25.

Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets.

Greenblatt DJ, Harmatz JS, Singh NN, Roth T, Harris SC, Kapil RP.

J Clin Pharmacol. 2013 Nov;53(11):1194-8. doi: 10.1002/jcph.159. Epub 2013 Sep 6.

PMID:
23939537
26.

Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.

Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP.

Clin Ther. 2013 May;35(5):604-11. doi: 10.1016/j.clinthera.2013.03.007. Epub 2013 Mar 28. Erratum in: Clin Ther. 2013 Jun;35(6):900.

PMID:
23541711
27.

Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.

Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci SV, Apseloff G, Kitzmiller J, Harris SC.

J Pain Symptom Manage. 2013 Jul;46(1):65-75. doi: 10.1016/j.jpainsymman.2012.06.014. Epub 2012 Sep 29.

PMID:
23026548
28.

Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.

Singh B, Singh R, Bandyopadhyay S, Kapil R, Garg B.

Colloids Surf B Biointerfaces. 2013 Jan 1;101:465-74. doi: 10.1016/j.colsurfb.2012.07.017. Epub 2012 Jul 21.

PMID:
23010056
29.

Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.

Kapil RP, Cipriano A, Michels GH, Perrino P, O'Keefe SA, Shet MS, Colucci SV, Noveck RJ, Harris SC.

Clin Drug Investig. 2012 Sep 1;32(9):583-92. doi: 10.2165/11633060-000000000-00000.

PMID:
22845044
30.

Formulation development of gastroretentive tablets of lamivudine using the floating-bioadhesive potential of optimized polymer blends.

Singh B, Garg B, Chaturvedi SC, Arora S, Mandsaurwale R, Kapil R, Singh B.

J Pharm Pharmacol. 2012 May;64(5):654-69. doi: 10.1111/j.2042-7158.2011.01442.x. Epub 2012 Feb 7.

PMID:
22471361
31.

Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation.

Kapil R, Dhawan S, Beg S, Singh B.

Drug Dev Ind Pharm. 2013 Mar;39(3):466-80. doi: 10.3109/03639045.2012.665926. Epub 2012 Mar 12.

PMID:
22409834
32.

Chronic rectal bleeding due to Lymphogranuloma venereum proctocolitis.

Geisler WM, Kapil R, Waites KB, Smith PD.

Am J Gastroenterol. 2012 Mar;107(3):488-9. doi: 10.1038/ajg.2011.464. No abstract available.

PMID:
22388034
33.

The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis.

Nuovo GJ, Hagood JS, Magro CM, Chin N, Kapil R, Davis L, Marsh CB, Folcik VA.

Mod Pathol. 2012 Mar;25(3):416-33. doi: 10.1038/modpathol.2011.166. Epub 2011 Oct 28.

34.

Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.

Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OO.

Drug Deliv. 2011 Nov;18(8):599-612. doi: 10.3109/10717544.2011.604686. Epub 2011 Oct 18.

PMID:
22008038
35.

Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects.

Singh B, Kapil R, Nandi M, Ahuja N.

Expert Opin Drug Deliv. 2011 Oct;8(10):1341-60. doi: 10.1517/17425247.2011.605120. Epub 2011 Jul 27. Review.

PMID:
21790511
36.

Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery.

Dhawan S, Kapil R, Singh B.

J Pharm Pharmacol. 2011 Mar;63(3):342-51. doi: 10.1111/j.2042-7158.2010.01225.x.

PMID:
21749381
37.

Design and development of paclitaxel-loaded bovine serum albumin nanoparticles for brain targeting.

Bansal A, Kapoor DN, Kapil R, Chhabra N, Dhawan S.

Acta Pharm. 2011 Jun;61(2):141-56. doi: 10.2478/v10007-011-0012-8.

PMID:
21684843
38.

Analysis of 3'-Terminal Region of Bean common mosaic virus Strains Infecting Common Bean in India.

Sharma P, Sharma PN, Kapil R, Sharma SK, Sharma OP.

Indian J Virol. 2011 Jun;22(1):37-43. doi: 10.1007/s13337-011-0038-z. Epub 2011 Jun 21.

39.

Developing micro-/nanoparticulate drug delivery systems using "design of experiments".

Singh B, Bhatowa R, Tripathi CB, Kapil R.

Int J Pharm Investig. 2011 Apr;1(2):75-87. doi: 10.4103/2230-973X.82395.

40.

Formulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride.

Singh B, Rani A, Babita, Ahuja N, Kapil R.

Sci Pharm. 2010 Apr-Jun;78(2):303-23. doi: 10.3797/scipharm.1001-04. Epub 2010 Apr 18.

41.

Development and validation of a spectrofluorimetric method for the estimation of rivastigmine in formulations.

Kapil R, Dhawan S, Singh B.

Indian J Pharm Sci. 2009 Sep;71(5):585-9. doi: 10.4103/0250-474X.58179.

42.

Development and evaluation of in situ gel-forming system for sustained delivery of insulin.

Dhawan S, Kapil R, Kapoor DN.

J Biomater Appl. 2011 Mar;25(7):699-720. doi: 10.1177/0885328209359959. Epub 2010 Mar 5.

PMID:
20207780
43.

Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications.

Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O.

Crit Rev Ther Drug Carrier Syst. 2009;26(5):427-521. Review.

PMID:
20136631
44.

Permanent Genetic Resources added to Molecular Ecology Resources Database 1 August 2009-30 September 2009.

Molecular Ecology Resources Primer Development Consortium, Abdoullaye D, Acevedo I, Adebayo AA, Behrmann-Godel J, Benjamin RC, Bock DG, Born C, Brouat C, Caccone A, Cao LZ, Casado-Amezúa P, Catanéo J, Correa-Ramirez MM, Cristescu ME, Dobigny G, Egbosimba EE, Etchberger LK, Fan B, Fields PD, Forcioli D, Furla P, Garcia de Leon FJ, García-Jiménez R, Gauthier P, Gergs R, González C, Granjon L, Gutiérrez-Rodríguez C, Havill NP, Helsen P, Hether TD, Hoffman EA, Hu X, Ingvarsson PK, Ishizaki S, Ji H, Ji XS, Jimenez ML, Kapil R, Karban R, Keller SR, Kubota S, Li S, Li W, Lim DD, Lin H, Liu X, Luo Y, Machordom A, Martin AP, Matthysen E, Mazzella MN, McGeoch MA, Meng Z, Nishizawa M, O'Brien P, Ohara M, Ornelas JF, Ortu MF, Pedersen AB, Preston L, Ren Q, Rothhaupt KO, Sackett LC, Sang Q, Sawyer GM, Shiojiri K, Taylor DR, Van Dongen S, Van Vuuren BJ, Vandewoestijne S, Wang H, Wang JT, Wang LE, Xu XL, Yang G, Yang Y, Zeng YQ, Zhang QW, Zhang Y, Zhao Y, Zhou Y.

Mol Ecol Resour. 2010 Jan;10(1):232-6. doi: 10.1111/j.1755-0998.2009.02796.x.

PMID:
21565018
45.

Development and evaluation of in situ gel forming system for sustained delivery of cyclosporine.

Dhawan S, Kapil R, Kapoor DN, Kumar M.

Curr Drug Deliv. 2009 Oct;6(5):495-504.

PMID:
19863490
46.

Flow, compressive, and bioadhesive properties of various blends of poly(ethylene oxide).

Kapil R, Kapoor DN, Dhawan S.

Drug Dev Ind Pharm. 2010 Jan;36(1):45-55. doi: 10.3109/03639040903037231.

PMID:
19566387
47.

Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics.

Singh B, Pahuja S, Kapil R, Ahuja N.

Acta Pharm. 2009 Mar;59(1):1-13. doi: 10.2478/v10007-009-0005-z.

PMID:
19304554
48.

Pharmacokinetic profile of dexloxiglumide.

Persiani S, D'Amato M, Jakate A, Roy P, Wangsa J, Kapil R, Rovati LC.

Clin Pharmacokinet. 2006;45(12):1177-88. Review.

PMID:
17112294
49.

Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.

Jakate AS, Roy P, Patel A, Abramowitz W, Persiani S, Wangsa J, Kapil R.

Br J Clin Pharmacol. 2005 Nov;60(5):498-507.

50.

The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender.

Roy P, Wangsa J, Patel A, Nolting A, Persiani S, Abramowitz W, Kapil R.

Int J Clin Pharmacol Ther. 2005 Sep;43(9):444-51.

PMID:
16163898

Supplemental Content

Support Center